By Colin Kellaher
Dermata Therapeutics shares jumped more than 50% in early trading Thursday after the biotechnology company said its Xyngari once-weekly, topical product candidate for the treatment of moderate-to-severe acne hit its goals in a late-stage study.
Shares of the San Diego company were recently changing hands at $2.05, up 52%.
Dermata said Xyngari met all three primary endpoints in the Phase 3 study by achieving a statistically significant difference when compared with placebo after 12 weeks.
Dermata said it plans to launch a second Phase 3 study in the second half of the year followed by an open-label extension study, adding that positive Phase 3 program will help support the filing of a new-drug application with the U.S. Food and Drug Administration.
The company said it also plans to hold talks with potential partners interested in securing future rights to Xyngari.
Dermata said it believes a once-weekly topical acne product like Xyngari could lead to improved patient compliance, as all current FDA-approved topical products need to be applied at least once or twice a day.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 27, 2025 09:57 ET (13:57 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.